DE69218956T2 - Förderung des hepatozytwachstums mit hepatozytwachstumsfaktor und gamma-interferon - Google Patents

Förderung des hepatozytwachstums mit hepatozytwachstumsfaktor und gamma-interferon

Info

Publication number
DE69218956T2
DE69218956T2 DE69218956T DE69218956T DE69218956T2 DE 69218956 T2 DE69218956 T2 DE 69218956T2 DE 69218956 T DE69218956 T DE 69218956T DE 69218956 T DE69218956 T DE 69218956T DE 69218956 T2 DE69218956 T2 DE 69218956T2
Authority
DE
Germany
Prior art keywords
hepatocyt
growth
promoting
growth factor
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69218956T
Other languages
English (en)
Other versions
DE69218956D1 (de
Inventor
Paula Jardieu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69218956D1 publication Critical patent/DE69218956D1/de
Application granted granted Critical
Publication of DE69218956T2 publication Critical patent/DE69218956T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE69218956T 1991-06-10 1992-05-19 Förderung des hepatozytwachstums mit hepatozytwachstumsfaktor und gamma-interferon Expired - Lifetime DE69218956T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/712,284 US5227158A (en) 1991-06-10 1991-06-10 Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
PCT/US1992/004227 WO1992022321A1 (en) 1991-06-10 1992-05-19 Hepatocyte growth stimulation with hepatocyte growth factor and gamma-interferon

Publications (2)

Publication Number Publication Date
DE69218956D1 DE69218956D1 (de) 1997-05-15
DE69218956T2 true DE69218956T2 (de) 1997-07-31

Family

ID=24861484

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69218956T Expired - Lifetime DE69218956T2 (de) 1991-06-10 1992-05-19 Förderung des hepatozytwachstums mit hepatozytwachstumsfaktor und gamma-interferon

Country Status (12)

Country Link
US (1) US5227158A (de)
EP (1) EP0606210B1 (de)
JP (1) JPH06508148A (de)
AT (1) ATE151292T1 (de)
AU (1) AU655653B2 (de)
CA (1) CA2109434A1 (de)
DE (1) DE69218956T2 (de)
DK (1) DK0606210T3 (de)
ES (1) ES2101849T3 (de)
GR (1) GR3023613T3 (de)
WO (1) WO1992022321A1 (de)
ZA (1) ZA923980B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
EP0642585B1 (de) * 1992-05-18 2005-12-28 Genentech, Inc. Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden
US5684136A (en) * 1992-05-18 1997-11-04 Genentech, Inc. Chimeric hepatocyte growth factor (HGF) ligand variants
DE69310525T2 (de) * 1992-09-16 1997-10-02 Genentech Inc Schutz gegen leberschäden mit hgf
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
JP3680114B2 (ja) * 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5696086A (en) * 1994-11-03 1997-12-09 Genentech, Inc. Methods and kits using macrophage stimulating protein
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
WO1997009997A1 (en) * 1995-09-12 1997-03-20 Genentech, Inc. Cystic fibrosis therapy
AU7254896A (en) * 1995-10-05 1997-04-28 Genentech Inc. Improved angiogenesis using hepatocyte growth factor
WO1997012628A1 (en) * 1995-10-05 1997-04-10 Genentech, Inc. Methods and compositions for treating vascular stenosis
CN1055517C (zh) * 1996-03-29 2000-08-16 唐禾天 叶片转子式发动机
US6280739B1 (en) 1996-04-18 2001-08-28 Genetics Institute, Inc. Method of inhibiting angiogenesis using secreted proteins
CA2258153C (en) * 1996-07-03 2004-08-17 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
EP2236156A3 (de) * 2001-01-09 2011-01-05 Baylor Research Institute Verfahren zur Behandlung und Diagnose von Psoriasis
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2430923A1 (de) 2002-06-05 2012-03-21 Genentech, Inc. Zusammensetzungen und Verfahren zum Leberwachstum und Leberschutz
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
EP1718677B1 (de) * 2003-12-19 2012-04-18 Genentech, Inc. Als therapeutika geeignete monovalente antikörperfragmente
US20050244959A1 (en) * 2004-03-30 2005-11-03 Anne Corlu Methods for inducing active hepatocytes proliferation, kits using such methods and uses of said kits
AU2005269758B2 (en) 2004-07-20 2011-11-03 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
NZ552485A (en) * 2004-08-05 2009-11-27 Genentech Inc Humanized anti-cmet antagonists
EP1838736B1 (de) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto-bindende moleküle
JP5222720B2 (ja) 2005-04-15 2013-06-26 ジェネンテック， インコーポレイテッド ＨＧＦβ鎖変異体
US7910555B2 (en) * 2006-07-07 2011-03-22 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4 ) receptor ligands
US8236761B2 (en) * 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
US20090226455A1 (en) * 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and her antagonists
EA201291482A1 (ru) 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
SG194932A1 (en) 2011-06-30 2013-12-30 Genentech Inc Anti-c-met antibody formulations
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
WO2013106577A2 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
AU2016215155A1 (en) 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
EP3254104B1 (de) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Verfahren zur auswahl therapeutischer moleküle
RU2720451C1 (ru) * 2019-05-06 2020-04-29 Анастасия Юрьевна Лаптиёва Способ стимуляции пострезекционной пролиферации гепатоцитов путем внутрипеченочного введения цианокобаламина

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
WO1988009673A1 (en) * 1987-06-02 1988-12-15 Schering Corporation Treatment of chronic type b hepatitis with a combination of recombinant human alpha and gamma interferons
US4973478A (en) * 1987-07-20 1990-11-27 Allelix Biopharmaceuticals, Inc. Treating inflammation with hepatocyte stimulating factor interferon β2
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders

Also Published As

Publication number Publication date
EP0606210B1 (de) 1997-04-09
ES2101849T3 (es) 1997-07-16
ZA923980B (en) 1993-12-01
GR3023613T3 (en) 1997-08-29
DK0606210T3 (da) 1997-05-05
DE69218956D1 (de) 1997-05-15
JPH06508148A (ja) 1994-09-14
CA2109434A1 (en) 1992-12-11
EP0606210A1 (de) 1994-07-20
AU655653B2 (en) 1995-01-05
US5227158A (en) 1993-07-13
ATE151292T1 (de) 1997-04-15
WO1992022321A1 (en) 1992-12-23
AU2144192A (en) 1993-01-12

Similar Documents

Publication Publication Date Title
DE69218956D1 (de) Förderung des hepatozytwachstums mit hepatozytwachstumsfaktor und gamma-interferon
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DE69433870D1 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
ATE219674T1 (de) Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
ATE104854T1 (de) Pharmazeutische zusammensetzung zur behandlung von osteoporose.
EP0253887A1 (de) Schwache interferondosierung für die erhöhung der impfstoffwirksamkeit.
ATE344023T1 (de) Transdermales therapeutisches pflaster mit capsaicin und seinen analogen
ATE140483T1 (de) Natürlicher killerzellen-stimulationsfaktor
BR8603315A (pt) Processo para produzir um implante de liberacao controlada;implante usado no processo;processo para purificar e concentrar hormonio de crescimento biologicamente ativo em uma forma adequada para incorporacao em um implante para administracao subcutanea
DE68905438D1 (de) Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose.
DE68909267D1 (de) Medikament zur Behandlung von fibrotischer Störung und antifibrotische Verbindung.
DE3851456T2 (de) Synergetische immunostimulierende Zusammensetzung und ihre Verwendung.
DK155491D0 (da) Behandling af patienter med kronisk leversygdom
Rguez-Moreno et al. A randomized trial of somatostatin (S) versus vasopresin plus nitroglycerin (V/N) in the treatment of acute variceal bleeding (AVB)
EP0180737A3 (en) Use of preparations containing gamma-interferon (ifn-gamma) for treating rheumatic diseases
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
ATE99954T1 (de) Verwendung bestimmter gamma-interferone zur behandlung von krebs des ovars.
GR3022945T3 (en) The use of BMY 14802 in the treatment of anxiety in benzodiazepine-withdrawn patients
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
NO911470D0 (no) Sammensetning og behandling med biologisk aktive peptiderog visse anioner.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 606210

Country of ref document: EP